echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New migraine favorite CGRP receptor antagonist Aimovig's sales are overtaken by Emgality

    New migraine favorite CGRP receptor antagonist Aimovig's sales are overtaken by Emgality

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    text | memory

    Calcitonin gene-related peptide (CGRP) is a popular target drug for migraine drug development.


    In addition to different indications, the above 7 drugs are also different in usage and frequency of use


    With the announcement of major companies' 2021 financial reports, the sales rankings of the above-mentioned CGRP receptor antagonists have also been released, as detailed in the table below


    Migraine is a common chronic neurovascular disease with episodic moderate to severe throbbing headache as the main clinical manifestation.


    As a new favorite in the field of migraine, CGRP receptor antagonists have undergone great changes in the market structure in 2020 and 2021.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.